Improved Osteoarthritis during Erenumab Treatment for Migraine: A Case Report.

ABSTRACT: Antibodies blocking the calcitonin gene-related peptide have revolutionized episodic and chronic migraine treatment. However, their applicability to non-cephalic pain conditions, such as osteoarthritis, is yet unknown. Osteoarthritis remains a clinical challenge, associated with high disability and limited treatment options. Like migraine, neuropeptides including calcitonin gene-related peptides are involved in its pathophysiology. We present the first case of a patient: a 73-year-old female with osteoarthritis who received monthly treatment for her chronic migraine with 140 mg subcutaneous erenumab, a monoclonal antibody against the receptor of calcitonin gene-related peptide. Though the migraine was unresponsive, the patient's arthritic symptoms improved drastically during treatment peri

SUBMITTER: Jantzen FT 

PROVIDER: S-EPMC10363275 | biostudies-literature | 2023 Jan-Dec

REPOSITORIES: biostudies-literature